A phase II study of VP-16-ifosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer

In Sook Woo, Young Suk Park, Sung Hee Kwon, Young Iee Park, Jung Ae Lee, Myung Jae Park, In Gyu Hyun, Ki Suk Jung, Hoon Sik Bae, Do Hoon Oh, Won Seok Kim, Keunchil Park, Chan Hyung Park, Ho Joong Kim, Yong Chul Ahn

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Background: At present the addition of thoracic irradiation to combination chemotherapy is a standard treatment for limited staged small cell lung cancer. However, there is still controversy about the optimum timing of chest irradiation. We conducted a phase II study of etoposide (VP-16)-ifosfamide-cisplatin (VIP) combination chemotherapy plus early concurrent thoracic irradiation for the patients with previously untreated limited small cell lung cancer in order to assess if the treatment modality could improve the response rate and the toxicity. Methods: Forty-four patients with limited small cell lung cancer were treated with etoposide-ifosfamide-cisplatin and concurrent thoracic irradiation. Combination chemotherapy consisted of etoposide 100 mg/m2 (on days 1-3), ifosfamide 1000 mg/m2 (on days 1 and 2) and cisplatin 100 mg/m2 (on day 1). Concurrent thoracic irradiation consisted of a total of 4000 cGy over 4 weeks starting on the first day of the first chemotherapy. All patients who showed a complete response were given prophylactic cranial irradiation for 2.5 weeks. Results: Forty-four of the 49 patients who entered the study from May 1994 to August 1998 were evaluable. The median age was 59 years and 40 patients had a performance status of 0 or 1. The median survival time was 22.5 months. Twenty-eight patients (62%) showed a complete response and 16 (38%) a partial response. Twenty-four patients (54%) developed grade 3 or 4 neutropenia; there was a 9% RTOG score 3 or 4 esophagitis. Conclusion: VIP combination chemotherapy and early concurrent thoracic irradiation for patients with limited stage small cell lung cancer revealed excellent antitumor response with tolerable toxicity.

Original languageEnglish
Pages (from-to)542-546
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume30
Issue number12
StatePublished - 2000

Keywords

  • Chemoradiotherapy
  • Ifosfamide
  • Small cell lung cancer

Fingerprint Dive into the research topics of 'A phase II study of VP-16-ifosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Woo, I. S., Park, Y. S., Kwon, S. H., Park, Y. I., Lee, J. A., Park, M. J., Hyun, I. G., Jung, K. S., Bae, H. S., Oh, D. H., Kim, W. S., Park, K., Park, C. H., Kim, H. J., & Ahn, Y. C. (2000). A phase II study of VP-16-ifosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer. Japanese Journal of Clinical Oncology, 30(12), 542-546.